ARIAD Pharmaceuticals (NASDAQ:ARIA) : 5 Wall Street analysts covering ARIAD Pharmaceuticals (NASDAQ:ARIA) believe that the average level the stock could reach for the short term is $10.4. The maximum price target given is $13 and the minimum target for short term is around $8, hence the standard deviation is calculated at $2.07.
Ariad Pharmaceuticals Inc. has lost 1.99% in the last five trading days and dropped 16.31% in the last 4 weeks. Ariad Pharmaceuticals Inc. is up 16.93% in the last 3-month period. Year-to-Date the stock performance stands at 18.24%.
ARIAD Pharmaceuticals (NASDAQ:ARIA) : 3 brokerage houses believe that ARIAD Pharmaceuticals (NASDAQ:ARIA) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on ARIAD Pharmaceuticals (NASDAQ:ARIA). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 2.2.
ARIAD Pharmaceuticals (NASDAQ:ARIA): The stock opened at $7.46 on Thursday but the bulls could not build on the opening and the stock topped out at $7.46 for the day. The stock traded down to $7.28 during the day, due to lack of any buying support eventually closed down at $7.39 with a loss of -0.94% for the day. The stock had closed at $7.46 on the previous day. The total traded volume was 2,708,178 shares.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).